A European Medicines Agency (EMA) committee is beginning a review of Sarepta Therapeutics‘ request for conditional approval of eteplirsen as a treatment for…
Articles by Margarida Azevedo, MSc
Patients with Duchenne muscular dystrophy and Becker muscular dystrophy treated with ACE inhibitors inhibitors (drugs that dilate blood vessels) had slower progression…
The U.K. charity Hope 4 Kidz has announced the successful completion of Matthew’s Milestone, a £75,000 (about $95,000) campaign to help a young boy with …
The Muscular Dystrophy Association (MDA) and Jiffy Lube service centers have been partners in the annual Muscle…
Exondys 51 (eteplirsen) was approved by the U.S. FDA for the treatment of Duchenne muscular dystrophy (DMD) on…
Summit Therapeutics has enrolled its first U.S. patients in its proof-of-concept Phase 2 clinical trial of ezutromid in…
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) favors the renewal of…
Actelion and ReveraGen BioPharma have entered an agreement in which Actelion has obtained the exclusive option to in-license ReveraGen’s…
Parent Project Muscular Dystrophy (PPMD) has designated the Center for Duchenne Muscular Dystrophy (CDMD) at UCLA its 12…
The Assistance Fund has announced the opening of a new service, called the Duchenne Muscular Dystrophy Financial Assistance Program, to help to…